News

Indivior Reports Strong Financial Performance

1 2 3 4 5

4.7

Andrew R. Michaud

• February 22, 2024

Indivior, a U.K.-listed pharmaceutical company, announced a significant turnaround in its financial performance, posting a fourth-quarter pretax profit as net revenue surged. The company is now contemplating the possibility of moving its primary listing to the U.S. by 2024.

Potential Move to U.S. Primary Listing

Indivior has commenced discussions with shareholders regarding the potential transition to a primary listing in the U.S., while maintaining a secondary listing in the U.K. This strategic move is driven by the current and anticipated growth opportunities for its proprietary products, which are predominantly focused on the U.S. market.

Key Financial Highlights

• In the fourth quarter, the company reported a pretax profit of $61 million, a stark contrast to the $256 million pretax loss in the same period a year ago.
• Net revenue for the quarter saw a robust increase to $293 million compared to $241 million previously.
• Full-year 2023 net revenue surged to $1.09 billion from $901 million in 2022.
• Notably, U.S. net revenue experienced significant growth, rising by 26% to $249 million in the fourth quarter and by 25% to $912 million for the full year.

Future Outlook

Looking ahead to 2024, Indivior anticipates net revenue to be in the range of $1.24 billion to $1.33 billion, showcasing a positive trajectory for the company's financial performance.

This strategic shift towards a potential U.S. primary listing underscores Indivior's commitment to capitalizing on growth opportunities and attracting more U.S. investors and analysts.

For more information, please contact Indivior directly.